Imperial College London
Alternate

ProfessorSadafGhaem-Maghami

Faculty of Medicine, Department of Surgery & Cancer

Professor of Gynaecological Oncology
 
 
 
//

Contact

 

+44 (0)20 3313 3267s.ghaem-maghami

 
 
//

Location

 

Hammersmith HouseHammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Barcroft:2021:humrep/deaa293,
author = {Barcroft, JF and Galazis, N and Jones, BP and Getreu, N and Bracewell-Milnes, T and Grewal, KJ and Sorbi, F and Yazbek, J and Lathouras, K and Smith, JR and Hardiman, P and Thum, M-Y and Ben-Nagi, J and Ghaem-Maghami, S and Verbakel, J and Saso, S},
doi = {humrep/deaa293},
journal = {Human Reproduction},
pages = {1093--1107},
title = {Fertility treatment and cancers-the eternal conundrum: a systematic review and meta-analysis.},
url = {http://dx.doi.org/10.1093/humrep/deaa293},
volume = {36},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - STUDY QUESTION: Does fertility treatment (FT) significantly increase the incidence of breast, ovarian, endometrial or cervical cancer? SUMMARY ANSWER: Overall, FT does not significantly increase the incidence of breast, ovarian or endometrial cancer and may even reduce the incidence of cervical cancer. WHAT IS KNOWN ALREADY: Infertility affects more than 14% of couples. Infertility and nulliparity are established risk factors for endometrial, ovarian and breast cancer, yet the association with FT is more contentious. STUDY DESIGN, SIZE, DURATION: A literature search was carried out using Cochrane Library, EMBASE, Medline and Google Scholar up to December 2019. Peer-reviewed studies stating cancer incidence (breast, ovarian, endometrial or cervical) in FT and no-FT groups were identified. Out of 128 studies identified, 29 retrospective studies fulfilled the criteria and were included (n = 21 070 337). PARTICIPANTS/MATERIALS, SETTING, METHODS: In the final meta-analysis, 29 studies were included: breast (n = 19), ovarian (n = 19), endometrial (n = 15) and cervical (n = 13), 17 studies involved multiple cancer types and so were included in each individual cancer meta-analysis. Primary outcome of interest was cancer incidence (breast, ovarian, endometrial and cervical) in FT and no-FT groups. Secondary outcome was cancer incidence according to specific fertility drug exposure. Odds ratio (OR) and random effects model were used to demonstrate treatment effect and calculate pooled treatment effect, respectively. A meta-regression and eight sub-group analyses were performed to assess the impact of the following variables, maternal age, infertility, study size, outliers and specific FT sub-types, on cancer incidence. MAIN RESULTS AND THE ROLE OF CHANCE: Cervical cancer incidence was significantly lower in the FT group compared with the no-FT group: OR 0.68 (95% CI 0.46-0.99). The incidences
AU  - Barcroft,JF
AU  - Galazis,N
AU  - Jones,BP
AU  - Getreu,N
AU  - Bracewell-Milnes,T
AU  - Grewal,KJ
AU  - Sorbi,F
AU  - Yazbek,J
AU  - Lathouras,K
AU  - Smith,JR
AU  - Hardiman,P
AU  - Thum,M-Y
AU  - Ben-Nagi,J
AU  - Ghaem-Maghami,S
AU  - Verbakel,J
AU  - Saso,S
DO  - humrep/deaa293
EP  - 1107
PY  - 2021///
SN  - 0268-1161
SP  - 1093
TI  - Fertility treatment and cancers-the eternal conundrum: a systematic review and meta-analysis.
T2  - Human Reproduction
UR  - http://dx.doi.org/10.1093/humrep/deaa293
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33586777
UR  - https://academic.oup.com/humrep/article/36/4/1093/6136066
VL  - 36
ER  -
Download